Opendata, web and dolomites

SDS-OmiProbe SIGNED

Revolutionary opto-biological methodology for aggressive HER2 cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SDS-OmiProbe project word cloud

Explore the words cloud of the SDS-OmiProbe project. It provides you a very rough idea of what is the project "SDS-OmiProbe" about.

optimization    single    laboratory    methodology    according    followed    vivo    disease    omiprobe    global    worldwide    volume    business    performed    market    discordance    trials    levels    resolution    breast    essence    world    tests    biomarker    optic    worth    diagnosed    tip    tools    sds    trend    invasive    million    efficacy    extracting    landscape    women    clinical    markers    opto       transparency    tissue    mortality    cancers    cells    tumours    fail    striking    device    detects    health    cellular    14    carries    concentration    samples    realization    biological    expensive    therapy    compelling    annually    independent    breakthrough    marker    accuracy    close    realize    companion    cell    rapid    soa    causes    organization    quantitative    report    morbidity    subject    gap    cancer    500    drugs    instant    approximately    projected    probe    her2    tool    billion    diagnostic    die    diagnosis    biopsies    biopsy    opportunity    revolutionary   

Project "SDS-OmiProbe" data sheet

The following table provides information about the project.

Coordinator
SDS OPTIC SPOLKA AKCYJNA 

Organization address
address: KONSTANTYNOW 1F
city: LUBLIN
postcode: 20 708
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Poland [PL]
 Project website https://sdsoptic.pl/
 Total cost 3˙985˙000 €
 EC max contribution 3˙985˙000 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2021-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SDS OPTIC SPOLKA AKCYJNA PL (LUBLIN) coordinator 3˙985˙000.00

Map

 Project objective

According to World Health Organization, cancer is one of the leading causes of morbidity and mortality worldwide, with approximately 14 million new cases per year. Breast cancer is the most common cancer among women, and is considered the second most common cancer overall. Each year about 1.7 million new cases are diagnosed worldwide and over 500,000 women die from the disease.

Current diagnosis methods of cancers fail to deliver objective results. Diagnosis require extracting tissue samples via invasive and expensive biopsy, followed by laboratory analysis, which are subject to significant levels of discordance.

SDS Optic presents a revolutionary opto-biological methodology that allows for instant cellular processes studies including in-vivo cancer diagnosis with single-cell resolution. SDS-OmiProbe detects presence and measures concentration levels of the HER2 cancer cells in breast tumours. It is a breakthrough device that carries the potential to address the challenges of SoA cancer markers diagnosis and biopsies. In essence, it is a laboratory test at the tip of a probe, but with greater accuracy, efficacy and quantitative results. SDS-OmiProbe may also be used as a companion diagnostic tool for targeted therapy and targeted therapy drugs.

There is compelling evidence that our novel SDS-OmiProbe is addressing a rapid growth trend in a high volume market. Based on Transparency Market Research Report the OmiProbe target market of HER2- biomarker tests is projected to be worth $4.6 billion, with 7.5 million HER2 marker tests performed annually worldwide.

In order to close the striking gap in the landscape of currently available cancer diagnostic and targeted therapy tools, and to realize the significant global business opportunity the objective of this project is optimization of the SDS-OmiProbe device, followed by realization of independent clinical trials and dissemination of the results.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SDS-OMIPROBE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SDS-OMIPROBE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More  

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More